BSE filing, NSE: NOVARTIND. Summary written from the filing by ALFA Finder's alert engine.
Novartis India Ltd: key numbers
- Share price
- ₹1,735.35
- Market cap
- ₹4,285 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1073.9×Sector 37.9×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Other merger & restructuring announcements
All →Rashi Peripherals Merger & Restructuring
Rashi Peripherals' board approved a share purchase and shareholders' agreement to sell 26% of subsidiary Rashi Semiconductor Solutions to Restar Corporation, Japan. Execution remains subject to approvals.
Span Divergent Merger & Restructuring Worth ₹5 Cr
Span Divergent's board approved selling its Mumbai immovable property to Glorious Sales LLP, an unrelated buyer, for up to Rs.5 Crore. Completion is expected by March 31, 2027.
- Value
- ₹5.00 Cr
- Execution
- Agreement to be executed on or before March 31, 2027; sale expected to complete on or before March 31, 2027
Sunteck Realty Merger & Restructuring Worth ₹0.01 Cr
Sunteck Realty incorporated a wholly owned subsidiary, Eminara Real Estates Private Limited. The Rs 1 lakh subscription is a small real estate expansion step.
- Value
- ₹0.01 Cr
Enviro Infra Engineers Merger & Restructuring Worth ₹0.01 Cr
Enviro Infra Engineers Limited, through its step-down subsidiary arrangement, incorporated WINDAXIS RENEWABLES PRIVATE LIMITED, a renewable power venture, with Rs.0.01 Crore cash consideration for 51% stake. The new entity will pursue wind, hydro and biomass power projects.
- Value
- ₹0.01 Cr
Enviro Infra Engineers Merger & Restructuring
Enviro Infra Engineers' step-down subsidiary Suyog Urja incorporated a wholly owned subsidiary, Windaxis Renewables, for wind and renewable power generation. The filing is an incorporation intimation with no stated capital outlay beyond nominal authorised capital.
Oceanic Foods Merger & Restructuring Worth ₹0.1 Cr
Oceanic Foods incorporated a wholly-owned subsidiary, Julyy's Foods International, in Jamnagar on November 5, 2026. It subscribed Rs. 10 lakh to its initial share capital.
- Value
- ₹0.10 Cr